MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-09-2026
KemPharm Operating Income 2011-2026 | KMPH
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income KemPharm
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -62.9 M | -87 M | -49.6 M | -42.6 M | 7.73 M | -5.61 M | -20.3 M | -55.9 M | -33.4 M | -37.5 M | -22.8 M | -16.4 M | -4.72 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.73 M | -87 M | -33.2 M |
Quarterly Operating Income KemPharm
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.14 M | -71 M | -5.36 M | - | -27.3 M | -23.8 M | -20.5 M | - | -15.4 M | -6.64 M | -12.8 M | - | -6.63 M | -24.8 M | -1.86 M | - | -2.22 M | 5.83 M | 6.96 M | - | -1.21 M | 2.59 M | -3.78 M | - | 3.23 M | -7.79 M | -11.4 M | - | -18 M | -13.9 M | -14.8 M | -8.15 M | -9.61 M | -8.22 M | -7.38 M | -10.8 M | -10.4 M | -9.28 M | -6.97 M | -7.28 M | -6.48 M | -5.96 M | -3.1 M | -7.49 M | -4.34 M | -3.04 M | -1.57 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.96 M | -71 M | -9.41 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Cerus Corporation
CERS
|
-8.68 M | $ 2.61 | 28.62 % | $ 497 M |  USA |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 97.03 | -6.21 % | $ 27.2 B | Germany |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 5.17 | 5.08 % | $ 820 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
231 M | $ 21.91 | -2.41 % | $ 3.63 B | USA |
 |
Athira Pharma
ATHA
|
-102 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | Britain |
 |
Cardiff Oncology
CRDF
|
-49 M | $ 1.72 | -0.87 % | $ 115 M | USA |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-102 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-130 M | - | - | $ 3.74 B | USA |
 |
Caladrius Biosciences
CLBS
|
-22.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.95 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-211 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Editas Medicine
EDIT
|
-160 M | $ 2.91 | -3.0 % | $ 258 M | USA |
 |
Edesa Biotech
EDSA
|
-7.01 M | $ 17.35 | -5.06 % | $ 55.5 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-4.12 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 3.03 | -5.02 % | $ 4.99 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
-71.8 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-34.4 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Evogene Ltd.
EVGN
|
-31 M | $ 0.79 | 1.66 % | $ 27.9 M | Israel |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-30.2 M | $ 0.57 | 0.07 % | $ 2.46 M | Israel |